SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.00    2.00 (0.51%)
Bid:
385.00
Ask:
399.00
Spread: 14.00 (3.636%)
Market Cap: £188.15m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

AGM Statement

19 Dec 2023 07:00

RNS Number : 1950X
Tristel PLC
19 December 2023
 

Tristel plc

("Tristel", the "Company", or the "Group")

AGM Statement, notice of results and planned CEO succession

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, will hold its Annual General Meeting at 11am today at the offices of Cavendish, One Bartholomew Close, London EC1A 7BL.

 

Paul Swinney, Chief Executive Officer, will address the meeting with the following update:

 

"I am pleased to report that the Company has had a record first half with revenue for the six months ending 31 December 2023 expected to be £20.7m, an increase of 18% compared to £17.5m in the first half of last year. Revenue growth has been delivered across all our geographical markets. Gross margin remains above 80% in line with our expectations.

 

"In the United States, Parker Laboratories, our manufacturing and distribution partner, completed its first production run for Tristel ULT in early October, following receipt of our FDA approval in June 2023. This has enabled Parker to stock its national distribution network and provide product to the first beta site users. We expect to make steady progress in building our customer base throughout the United States during the second half of our financial year. We remain very excited about our prospects as we begin serving the largest healthcare market in the world.

 

"The business is performing strongly on all fronts and the confidence that we expressed in October in our medium-term outlook remains unchanged. With the growth possibilities for our business stronger than ever, and as a business with no debt and forecast cash balances of approximately £10.4m after payment of this year's final dividend on 22 December, we are in a strong position to capitalise upon our global leadership position in the medical device decontamination market." 

 

Notice of Results

The Company's unaudited interim results will be announced on 26 February 2024.

 

CEO succession planning

In addition, Paul Swinney, co-founder of the business in 1993 and Group CEO for the past thirty years, has informed the Board of his intention to retire within the next twelve months. Paul will continue in his post until a successor is appointed and has committed to remain available thereafter to support and advise the business in executing a successful transition in the leadership of the Group. The Board has, therefore, initiated a formal succession process, supported by the global organisational consulting firm The Coulter Partnership, that will consider both external and internal candidates.

 

The Group's new CEO will join a strong executive leadership team with significant functional and market experience, gained from within and outside the business.

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Chief Financial Officer

 

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Charlotte Edgar

Mob: 07884 664 686

Alice Woodings

Mob: 07407 804 654

Cavendish Capital Markets Limited

Tel: 020 7220 0500

Geoff Nash/Charlie Beeson (Corporate Finance)

Sunila de Silva (ECM)

 

 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMEVLFFXLLXFBL
Date   Source Headline
11th Dec 201212:56 pmRNSResult of AGM
29th Oct 20127:00 amRNSFinal Results
29th Aug 20127:00 amRNSDirector/PDMR Shareholding
8th Aug 20127:00 amRNSDirectorate Change
2nd Aug 20127:00 amRNSNew website
23rd Jul 201210:29 amRNSDirector/PDMR Shareholding
23rd Jul 20127:00 amRNSTrading update
9th Jul 20127:00 amRNSSupply&distribution agreement - Basan Germany GmbH
25th Jun 20127:00 amRNSDirectorate Change
15th Jun 201211:40 amRNSDirectors' Shareholdings
15th Jun 20127:00 amRNSTrading Update
12th Jun 20127:00 amRNSResult of Clinical Study
30th Apr 20129:00 amRNSDirectors' Dealings
3rd Apr 20127:00 amRNSTermination of supply arrangement
30th Mar 20127:00 amRNSResults of Clinical Study
12th Mar 20127:00 amRNSHalf Yearly Report
8th Mar 20127:00 amRNSNotice of Results
11th Jan 20123:17 pmRNSDirector/PDMR Shareholding
4th Jan 20128:50 amRNSDirector/PDMR Shareholding
23rd Dec 201112:16 pmRNSDirector/PDMR Shareholding
21st Dec 20113:40 pmRNSGrant of Share Options
13th Dec 201111:52 amRNSResult of AGM
8th Dec 20114:24 pmRNSDirector/PDMR Shareholding
25th Nov 20111:22 pmRNSDirector/PDMR Shareholding
22nd Nov 20117:00 amRNSDirector's Dealing
11th Nov 201110:27 amRNSDirector/PDMR Shareholding
4th Nov 20112:10 pmRNSDirector/PDMR Shareholding
24th Oct 20119:51 amRNSDirector/PDMR Shareholding
24th Oct 20117:01 amRNSDirectorate Change
24th Oct 20117:00 amRNSFinal Results
7th Sep 20117:00 amRNSFull regulatory approval for Fuse and Jet in China
9th Aug 20118:37 amRNSDirector's Shareholding
8th Aug 20117:00 amRNSCash inflow regarding R&D spend
25th Jul 20117:00 amRNSTrading update & notice of results
6th Jun 20117:00 amRNSApproval for Wipes System from VAH in Germany
12th May 20118:00 amRNSChina Licence received
6th May 20117:00 amRNSDirector Dealing
4th May 20112:38 pmRNSDirector Dealing
4th May 20117:00 amRNSDirector/PDMR Shareholding
28th Apr 20112:08 pmRNSTrading Update
14th Mar 20117:00 amRNSHalf Yearly Report
31st Jan 20117:00 amRNSCompletion of Clean Room & Notice of Results
30th Dec 20107:00 amRNSTermination of Agreement with Clorox
14th Dec 201011:15 amRNSResult of AGM
22nd Nov 201010:12 amRNSResult of General Meeting
12th Nov 201010:55 amRNSDirector/PDMR Shareholding
8th Nov 20103:06 pmRNSDirector Shareholding
5th Nov 201011:32 amRNSPlacing to raise £3.9million
18th Oct 20107:00 amRNSFinal Results
9th Sep 20107:00 amRNSTrading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.